The effect of L-arginine and L-NAME on myocardial capillary density in normal rats

Khazaei, Majid; Moshayedi, Muhammad Amin; Teimouri Jervekani, Massoud; Aghili, Shahrzad; Montazer, Saeed; Mehdipour Dastjerdi, Roshanak; Hashemzehi, Fazlolah; Hashemi Jazi, Hourossadat

The effect of L-arginine and L-NAME on myocardial capillary density in normal rats

Authors

¹ Department of Physiology, Isfahan University of Medical Sciences, Isfahan, Iran

² Student Research Center, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: This study evaluated the effect of L-arginine (Nitric Oxide (NO) precursor) and L-NG-Nitroarginine Methyl Ester (L-NAME) (NO synthase inhibitor) on myocardial capillary density in normal rats.
Materials and Methods: Eighteen male rats were divided into three groups: Group 1: Received L-NAME (10 mg/kg/day; ip), Group 2: Received L-arginine (50 mg/kg/day; ip), and Group 3 (control) received normal saline. After 3 weeks, blood samples were taken and myocardial capillary density was evaluated using immunohistochemistry method.
Results: Serum NO concentration in control group was 6.45 ± 0.44 μmol/lit. Treatment of animals with L-arginine increased serum NO concentration (7.90 ± 0.75 vs. 6.45 ± 0.44 μmol/lit, respectively) and L-NAME decreased (4.86 ± 0.40 vs. 6.45 ± 0.44 μmol/lit, respectively) compare to control group. L-arginine significantly increased serum vascular endothelial growth factor (VEGF) concentration (353.01 ± 7.03 vs. 100.5 ± 6.61 pg/ml; P < 0.05), however, did not change myocardial capillary density.
Conclusion: Although L-arginine alters some serum angiogenic factors, either L-arginine or L-NAME could not improve myocardial capillary density in normal rats.

Keywords

References

1.	Hogan P, Dall T, Nikolov P, American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26:917-32.
2.	Bax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO, Barrett EJ, et al. Screening for coronary artery disease in patients with diabetes. Diabetes Care 2007;30:2729-36.
3.	Satchell SC, Mathieson PW. Angiopoietins: Microvascular modulators with potential roles in glomerular pathophysiology. J Nephrol 2003;16:168-78. [PUBMED]
4.	Bates DO, Hillman NJ, Williams B, Neal CR, Pocock TM. Regulation of microvascular permeability by vascular endothelial growth factors. J Anat 2002;200:581-97. [PUBMED]
5.	Kawamura A, Horie T, Tsuda I, Abe Y, Yamada M, Egawa H, et al. Clinical study of therapeutic angiogenesis by autologous peripheral blood stem cell (PBSC) transplantation in 92 patients with critically ischemic limbs. J Artif Organs 2006;9:226-33. [PUBMED]
6.	Pistea A, Bakker EN, Spaan JA, Hardeman MR, van Rooijen N, VanBavel E. Small artery remodeling and erythrocyte deformability in L-NAME-induced hypertension: Role of transglutaminases. J Vasc Res 2008;45:10-8. [PUBMED]
7.	Hutchison SJ, Reitz MS, Sudhir K, Sievers RE, Zhu BQ, Sun YP, et al. Chronic dietary L-Arginine prevents endothelial dysfunction secondary to environmental tobacco smoke in normocholesterolemic rabbits. Hypertension 1997;29:1186-91. [PUBMED]
8.	Khazaei M, Nematbakhsh M. Serum level of vascular endothelial growth factor is increased by estrogen replacement therapy in normotensive and DOCA-Salt hypertensive ovariectomized rats. Clin Chim Acta 2006;365:206-10. [PUBMED]
9.	Cengel A, Sahinarslan A. Nitric oxide and cardiovascular system. Anadolu Kardiyol Derg 2006;6:364-8. [PUBMED]
10.	Ghosh S, Khazaei M, Moien-Afshari F, Ang LS, Granville DJ, Verchere CB, et al. Moderate exercise attenuates caspase-3 activity, oxidative stress, and inhibits progression of diabetic renal disease in db/db mice. Am J Physiol Renal Physiol 2009;296:F700-8. [PUBMED]
11.	Moien-Afshari F, Ghosh S, Elmi S, Khazaei M, Rahman MM, Sallam N, et al. Exercise restores coronary vascular function independent of myogenic tone or hyperglycemic status in db/db mice. Am J Physiol Heart Circ Physiol 2008;295:H1470-80. [PUBMED]
12.	Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 2001;26:25-35. [PUBMED]
13.	Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445-50. [PUBMED]
14.	Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7. [PUBMED]
15.	Cooke JP. NO and angiogenesis. Atheroscler Suppl 2003;4:53-60. [PUBMED]
16.	Morbidelli L, Chang CH, Douglas JG, Granger HJ, Ledda F, Ziche M. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol 1996;270:H411-5. [PUBMED]
17.	Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 1994;94:2036-44. [PUBMED]
18.	Dulak J, Józkowicz A, Dembinska-Kiec A, Guevara I, Zdzienicka A, Zmudzinska-Grochot D, et al. Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000;20:659-66.
19.	Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998;274:H1054-8. [PUBMED]
20.	Babaei S, Teichert-Kuliszewska K, Monge JC, Mohamed F, Bendeck MP, Stewart DJ. Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor. Circ Res 1998;82:1007-15. [PUBMED]
21.	Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ, et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997;99:2625-34. [PUBMED]

Advanced Biomedical Research